KRYS - Krystal Biotech GAAP EPS of -$1.99 misses by $0.93

Krystal Biotech press release (NASDAQ:KRYS): Q1 GAAP EPS of -$1.99 misses by $0.93. Cash, cash equivalents, and investments totaled $468M on March 31, 2022. “Our primary objective in 2022 is to prepare for the potential approval and launch of B-VEC in the U.S.” said Krish S. Krishnan, chairman and chief executive officer. “We also remain focused on our B-VEC global regulatory filings and advancing our robust pipeline and we are fortunate to have a team with unwavering commitment and the financial strength to do so.”

For further details see:

Krystal Biotech GAAP EPS of -$1.99 misses by $0.93